Aims and Scope of ACS Medicinal Chemistry Letters
ACS Medicinal Chemistry Letters is a peer-reviewed academic journal in the field of medicinal chemistry. Founded in 2009, this online journal is published monthly by the American Chemical Society. The Editor-in-Chief is Dennis C. Liotta (Emory University, Atlanta, Georgia, USA). Less
Key Metrics
CiteScore 

6.6
Eigenfactor 

0.01 - 0.05
Impact Factor 

< 5
SJR 

Q2Biochemistry

SNIP 

0.93
Recommended pre-submission checks
Powered by 

Topics Covered on ACS Medicinal Chemistry Letters
ACS Medicinal Chemistry Letters Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
SJR
| Overview | |
| Publisher | AMER CHEMICAL SOC |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2010 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in ACS Medicinal Chemistry Letters ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in ACS Medicinal Chemistry Letters
Discovery of 2H-Pyrrolo[3,4‑c]pyridin-3-one Derivatives as Type-III c‑MET Inhibitors Enabled by Free-Energy Perturbation Calculations.
- 11 Jun 2026
- ACS medicinal chemistry letters
Optimization Leading to a Potent and Selective Cbl‑b Inactive-State Inhibitor That Demonstrated In Vivo Efficacy.
- 11 Jun 2026
- ACS medicinal chemistry letters
Degrading Immune Checkpoints and Coordinating Oncogenic Signaling: Emerging Strategies in Cancer Therapy.
- 11 Jun 2026
- ACS medicinal chemistry letters
Design and Synthesis of Phosphonoproline-Proline Bioisosteric Mimetics of Proline Dimers: Pseudopeptide Constructs as Potential Inhibitors of the Zn-Metalloprotease PPEP-1 Associated with <i>Clostridioides difficile</i>
- 11 Jun 2026
- ACS Medicinal Chemistry Letters
Development of Novel 17β-HSD10 Inhibitors and Their Evaluation in an In Vitro Model of Alzheimer's Disease.
- 11 Jun 2026
- ACS medicinal chemistry letters
Novel Compounds as TREM2 Modulators for Treating Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, and Nasu-Hakola Disease.
- 11 Jun 2026
- ACS medicinal chemistry letters
Discovery of 2H-Pyrrolo[3,4‑c]pyridin-3-one Derivatives as Type-III c‑MET Inhibitors Enabled by Free-Energy Perturbation Calculations.
- 11 Jun 2026
- ACS medicinal chemistry letters
Optimization Leading to a Potent and Selective Cbl‑b Inactive-State Inhibitor That Demonstrated In Vivo Efficacy.
- 11 Jun 2026
- ACS medicinal chemistry letters
Degrading Immune Checkpoints and Coordinating Oncogenic Signaling: Emerging Strategies in Cancer Therapy.
- 11 Jun 2026
- ACS medicinal chemistry letters
Design and Synthesis of Phosphonoproline-Proline Bioisosteric Mimetics of Proline Dimers: Pseudopeptide Constructs as Potential Inhibitors of the Zn-Metalloprotease PPEP-1 Associated with <i>Clostridioides difficile</i>
- 11 Jun 2026
- ACS Medicinal Chemistry Letters
Development of Novel 17β-HSD10 Inhibitors and Their Evaluation in an In Vitro Model of Alzheimer's Disease.
- 11 Jun 2026
- ACS medicinal chemistry letters
Novel Compounds as TREM2 Modulators for Treating Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, and Nasu-Hakola Disease.
- 11 Jun 2026
- ACS medicinal chemistry letters